A Clinical Study of Arfolitixorin in Patients With mCRC

This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 60 people will participate in the study. There is already a standard therapy for treatment of colorectal cancer. This therapy contains a combination of the medicines leucovorin, fluorouracil, oxaliplatin and bevacizumab. The sponsoring company is developing the new therapy called arfolitixorin. In this study, patients with colorectal cancer will be given arfolitixorin instead of the standard treatment leucovorin.

Trial Details

NCT ID
NCT06922383
Phase
PHASE1 / PHASE2
Sponsor
Isofol Medical AB
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • arfolitixorin (ARFOX + bevacizumab)
Locations (sample)
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Signed ICF and ability to comply with protocol requirements.
  • Histologically confirmed RAS mutant, MSS/pMMR, colorectal adenocarcinoma with metastatic disease, eligible for first-line therapy with 5-FU, oxalip…
  • Tumor specimen (formalin-fixed, paraffin-embedded \[FFPE\]) available.
  • Adequate heart function as defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →